Comparison Of Leading COVID-19 Vaccine Candidates For U.S. Vaccine Distribution
Updated March 2021
This quick reference guide compares the following leading COVID-19 vaccines and vaccine candidates in terms of administration, efficacy, ancillary supplies, and other key factors.
- Pfizer/BioNTech: 95%
- Moderna: 94.5%
- AstraZeneca: Testing showed 90% for initial half-strength dose, 62% for two standard-dose shots
- Johnson & Johnson: 72%
- Novavax: Unknown
- Sanofi/GlaxoSmithKline: In 2020, Sanofi/GSK announced disappointing results for people over 50 and planned to start a new Phase 2 trial in 2021 with different formulation
Download the PDF for further details such as vaccine names, vaccine types, distribution, storage, and more.